GlassScriptPhysician profile
Kevin J Kohan
NPI 1487776746
$4,014.05
in general payments reported to CMS, 2019-2025
26 companies · $858 in 2025
The $858 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $744 · 2020: $162 · 2021: $207 · 2022: $572 · 2023: $408 · 2024: $1,064 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,329.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,038.35 | 2021-2025 | Intellis Adaptivestim |
| Boston Scientific Corporation | $754.72 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Vertos Medical, INC. | $270.05 | 2024 | Mild Device Kit |
| Abbott Laboratories | $176.56 | 2019-2025 | Proclaim |
| Si-Bone, INC. | $123.52 | 2019 | |
| Ibsa Pharma INC. | $96.39 | 2023 | Licart |
| Saluda Medical Americas, INC. | $93.38 | 2024 | Evoke |
| Depuy Synthes Sales INC. | $65.20 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.29 | 2023-2024 | Relistor |
| Merz North America, INC. | $38.23 | 2019 | |
| Scilex Pharmaceuticals INC. | $32.20 | 2019 | |
| Daiichi Sankyo INC. | $30.19 | 2019 | |
| Fidia Pharma USA INC. | $26.79 | 2020 | |
| Medtronic USA, INC. | $25.61 | 2019 | |
| Curonix LLC | $23.31 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Assertio Therapeutics, INC. | $21.89 | 2019 | |
| Collegium Pharmaceutical, INC. | $19.25 | 2024 | Xtampza |
| Horizon Therapeutics Plc | $17.67 | 2019 | |
| Lilly USA, LLC | $17.65 | 2022 | |
| Zyla Life Sciences, INC. | $17.47 | 2020 | |
| Spr Therapeutics, INC | $17.46 | 2019 | |
| Amgen INC. | $16.74 | 2019 | |
| Allergan, INC. | $13.77 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.00 | 2019 | |
| Biodelivery Sciences International, INC. | $10.89 | 2019 | |
| Forte Bio-Pharma LLC | $9.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Kohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.